Indacaterol
ARCAPTA
Pronunciation: in-da-KA-ter-ol (ar-KAP-ta)
What it isOnce-daily long-acting beta-2 agonist; COPD maintenance.
Why this oneTwenty-four-hour bronchodilation with a rapid onset, unusual for a LABA.
What limits itNever as monotherapy in asthma. Cough immediately after inhalation is characteristic.
Indacaterol prescription history
Animated chart of estimated U.S. prescriptions per year, Asthma/COPD meds (1924–2026). Indacaterol enters in 2011 (estimated).
FDA-approved for
- COPD (2011)
NO BOXED WARNINGS
Principal riskNever as monotherapy in asthma; post-inhalation cough
Classes and tags
Clinical profile
Defining liabilityAdrenergic cardiovascular effects and paradoxical bronchospasm
Open Indacaterol in the interactive console ↗
Self-check
- What characteristic symptom can occur immediately after indacaterol inhalation?
Cough. - May indacaterol be used alone in asthma?
No.